Back to Treatments

Treatment

Rituximab with CODOX-M/IVAC

1
Conditions
2
Trials
4,000
Participants
25%
Average Safety

Condition Evidence

Burkitt lymphoma

2 trials · 4,000 participants

88% effectiveness · 25% safety
Rituximab with CODOX-M/IVAC | DFDA